NEW ORLEANS--(BUSINESS WIRE)--ARYx Therapeutics (NASDAQ:ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide reductase (VKOR) inhibitor in Phase 2/3 development for the treatment of patients at risk of forming dangerous blood clots, were presented this week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA. The data featured in these presentations indicate that ATI-5923 has potential advantages over the leading drug warfarin, including possible reduction of drug-drug interactions (DDIs), more predictable dosing and better anticoagulation control.
